On December 7th, Fipra sponsored a Chatham House discussion with Jonathan Mogford, Director of Policy at MHRA (Medicines and Healthcare Products Regulatory Agency), on future EU-UK co-operation on pharmaceutical policy post-Brexit.

Mogford is responsible for leading on the agency’s international work, including defining the UK’s future engagement with the EU in this area. He also chairs the regulatory “deep dive” group reporting to the Ministerial Life Sciences Brexit group.

Over the last 15 years, the pharmaceutical industry in the EU Member States has almost doubled its production (from €125 billion to €225 billion).

Mogford explained the UK governments’ position in favour of continued close regulatory collaboration post Brexit between the UK and EU on pharmaceuticals and medical devices, as this was outlined by UK Ministers in July in the Financial Times and other Ministerial statements.